Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023

A monoclonal antibody for universal respiratory syncytial virus prophylaxis in infants has recently been licensed. We share our experiences of integrating nirsevimab into the regional immunisation programme in Galicia, Spain. After a 3-week hospital-based immunisation campaign with flexible individu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Euro surveillance : bulletin européen sur les maladies transmissibles Jg. 28; H. 49; S. 1
Hauptverfasser: Martinón-Torres, Federico, Mirás-Carballal, Susana, Durán-Parrondo, Carmen
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Sweden Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS) 07.12.2023
European Centre for Disease Prevention and Control (ECDC)
Schlagworte:
Antibodies, Monoclonal - therapeutic use
Antiviral Agents - therapeutic use
Babies
Clinical outcomes
Disease prevention
Humans
Immunization
Infant
Monoclonal antibodies
Palivizumab - therapeutic use
Rapid Communication
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - prevention & control
Respiratory Syncytial Virus, Human
Respiratory Syncytial Viruses
Spain
Spain
Galicia Spain
Respiratory Syncytial Virus
immunoprophylaxis
nirsevimab
implementation
long-acting monoclonal antibodies
ISSN:1560-7917, 1025-496X, 1560-7917
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A monoclonal antibody for universal respiratory syncytial virus prophylaxis in infants has recently been licensed. We share our experiences of integrating nirsevimab into the regional immunisation programme in Galicia, Spain. After a 3-week hospital-based immunisation campaign with flexible individualised appointments and educational activities, nirsevimab uptake was 97.5% in the high-risk group, 81.4% in the catch-up group and 92.6% in infants born during the campaign. This successful implementation strategy can serve as a model and may inform other countries’ programmatic deliberations.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Correspondence: Federico Martinón-Torres (federico.martinon.torres@sergas.es)
ISSN:1560-7917
1025-496X
1560-7917
DOI:10.2807/1560-7917.ES.2023.28.49.2300606